INO Past Earnings image   This INO past earnings page last updated 11/10/2022
INO Past Earnings
PeriodPast Earnings DateGAAP
Q3 202211/8/2022-0.150
Q2 20228/9/2022-0.460
Q1 20225/10/2022-0.360
Q4 20213/1/2022-0.500
Q3 202111/9/2021-0.290
Q2 20218/9/2021-0.390
Q1 20215/10/2021-0.270
Q4 20203/1/2021-0.140
Q3 202011/9/2020-0.260
Q2 20208/10/2020-0.200
Q1 20205/11/2020-0.260
Q4 20193/12/2020-0.380
Q3 201911/12/2019-0.250
Q2 20198/8/2019-0.300
Q1 20195/9/2019-0.300
Q4 20183/12/2019-0.34
Q3 201811/8/2018-0.27
Q2 20188/7/2018-0.08
Q1 20185/9/2018-0.36
Q4 20173/14/2018-0.25
Q3 201711/8/2017-0.4
Q2 20178/8/2017-0.13
Q1 20175/10/2017-0.31
Q4 20163/15/2017-0.35
Q3 201611/9/2016-0.28
Q2 20168/8/2016-0.26
Q1 20165/9/2016-0.11
Q4 20153/14/2016-0.25
Q3 201511/9/20150.07
Q2 20158/10/2015-0.11
Q1 20155/11/2015-0.18
Q4 20143/16/2015-0.12
Q3 201411/10/2014-0.12
Q2 20148/11/2014-0.17
Q1 20145/12/2014-0.05
Q4 20133/17/2014-0.07
Q3 201311/12/2013-0.160
Q2 20138/9/2013-0.06
Q1 20135/10/2013-0.06
Q4 20123/18/20130.000
Q3 201211/7/2012-0.05
INO Past Revenue
PeriodPast Earnings DateGAAP
Q3 202211/8/20220.01B
Q2 20228/9/20220.00B
Q1 20225/10/20220.00B
Q4 20213/1/20220.00B
Q3 202111/9/20210.00B
Q2 20218/9/20210.00B
Q1 20215/10/20210.00B
Q4 20203/1/20210.01B
Q3 202011/9/20200.24B
Q2 20208/10/20200.00B
Q1 20205/11/20200.00B
Q4 20193/12/20200.00B
Q3 201911/12/20190.00B
Q2 20198/8/20190.00B
Q1 20195/9/20190.00B
Q4 20183/12/20192.50M
Q3 201811/8/20182.00M
Q2 20188/7/201824.45M
Q1 20185/9/20181.53M
Q4 20173/14/20188.79M
Q3 201711/8/20172.65M
Q2 20178/8/201720.41M
Q1 20175/10/201710.38M
Q4 20163/15/20178.51M
Q3 201611/9/201612.54M
Q2 20168/8/20166.20M
Q1 20165/9/20168.11M
Q4 20153/14/20165.93M
Q3 201511/9/201524.18M
Q2 20158/10/20155.29M
Q1 20155/11/20155.17M
Q4 20143/16/20152.50M
Q3 201411/10/20141.80M
Q2 20148/11/20143.80M
Q1 20145/12/20142.36M
Q4 20133/17/20141.70M
Q3 201311/12/20130.01B
Q2 20138/9/2013785610
Q1 20135/10/20131.45M
Q4 20123/18/20130.00B
Q3 201211/7/2012855000
Quotes delayed 20 minutes

Email EnvelopeFree INO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Inovio Pharmaceuticals (INO) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

INSM Past Earnings
INSP Past Earnings
INVA Past Earnings
INVO Past Earnings
INZY Past Earnings
IONS Past Earnings
IOVA Past Earnings
IPSC Past Earnings
IQV Past Earnings
IRIX Past Earnings

INO Past Earnings Q&A

What was the best and worst INO past earnings results?
For Inovio Pharmaceuticals, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest INO past earnings result in our data set was 0.07/share posted in Q3 2015, while the lowest was in Q4 2021 when INO posted -0.500/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q3 2020 when INO reported 0.24B in revenue, while the quarter with the lowest revenue in our data set was Q2 2019 at 0.00B of revenue.

  Suggested answer: There are 41 INO past earnings results in our data set.

On this page we presented the INO past earnings date information for Inovio Pharmaceuticals. Reviewing that INO Past Earnings for the company, we see that the highest past earnings result in our data set was in Q3 2015, when INO posted gaap of 0.07/share. Meanwhile the lowest INO past earnings result was in Q4 2021, when INO posted gaap of -0.500/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q3 2020 when INO reported 0.24B in revenue, while the smallest revenue quarter was Q2 2019 when INO reported 0.00B in revenue.

Any self directed investor doing their due diligence on INO or any other given stock can benefit from researching all of the Inovio Pharmaceuticals past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you to make it easy for investors to investigate Inovio Pharmaceuticals past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for INO. Thanks for visiting, and the next time you need to research INO past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: Funds Holding BBMC, Institutional Holders of AGX, WMS Stock Predictions.


INO Past Earnings | | Copyright © 2020 - 2022, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.